Trust Co. of Toledo NA OH Has $783,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Trust Co. of Toledo NA OH lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,416 shares of the medical equipment provider’s stock after selling 463 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in Zimmer Biomet were worth $783,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ZBH. Geode Capital Management LLC grew its holdings in Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares during the period. M&T Bank Corp grew its holdings in Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after purchasing an additional 8,709 shares during the period. National Pension Service grew its holdings in Zimmer Biomet by 3.8% during the third quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock worth $39,893,000 after purchasing an additional 13,612 shares during the period. River Global Investors LLP grew its holdings in Zimmer Biomet by 31.3% during the third quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock worth $2,276,000 after purchasing an additional 5,030 shares during the period. Finally, Border to Coast Pensions Partnership Ltd grew its holdings in Zimmer Biomet by 4.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock worth $16,711,000 after purchasing an additional 6,623 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ZBH. Raymond James reduced their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Oppenheimer reduced their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Barclays reduced their price objective on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Evercore ISI reduced their price objective on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Finally, BTIG Research reduced their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Trading Up 0.8 %

Shares of ZBH stock opened at $105.36 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $100.67 and a 1 year high of $133.90. The stock has a market cap of $20.97 billion, a P/E ratio of 20.03, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a 50 day simple moving average of $107.97 and a 200 day simple moving average of $108.00.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the previous year, the business earned $1.65 earnings per share. The company’s revenue was up 4.1% on a year-over-year basis. On average, research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.91%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.